There is a significant need for new treatments for patients with relapsed acute myeloid leukemia, a rare cancer of the blood that is more common in older adults. UNC Lineberger Comprehensive Cancer Center researchers recently ...
Jan 4, 2019
0
3
Findings from a new study by researchers at the National Cancer Institute (NCI) show that patients treated with chemotherapy for most solid tumors during 2000-2014 experienced an increased risk of therapy-related myelodysplastic ...
Dec 20, 2018
0
6
Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia (AML).
Dec 8, 2018
0
138
At the American Society of Hematology (ASH) Annual Meeting, Cleveland Clinic medical hematologist and oncologist Aziz Nazha, M.D., will present results of a personalized prediction model that surpassed current prediction ...
Dec 3, 2018
0
1
Older patients with acute myeloid leukemia (AML) often aren't healthy enough to receive intensive chemotherapy, and gentler treatments aren't very effective in treating this aggressive blood cancer.
Nov 29, 2018
0
4
Researchers from the Princess Máxima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ. Rather, the location of DNA mutations is relevant. Using ...
Nov 29, 2018
0
8
Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients ...
Nov 28, 2018
0
72
Although it has long been recognized that mutations of gene NPM1 play an important role in acute myeloid leukemia, no one has determined how the normal and the mutated forms of the protein NPM1 function.
Nov 13, 2018
0
8
Think of energy metabolism like a party popper: Ripping something apart releases a bang. Most of your cells rip apart sugar to release the "bang" of energy. Sometimes they rip apart fats, and in a pinch, cells can even metabolize ...
Nov 12, 2018
0
1201
A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated an encouraging response rate and overall survival in patients with relapsed or refractory ...
Nov 8, 2018
0
0
